Summary Reversal of multidrug resistance (MDR) may offer a means of increasing the effectiveness of tumour chemotherapy. A variety of recent evidence indicates that cytokines may be particularly useful in this endeavour. To investigate the molecular mechanism by which cytokines may sensitise multidrug-resistant colon carcinoma cells, HCT15 and HCT116, to treatment with MDR-related drugs, we evaluated the effects of the human cytokines tumour necrosis factor a (TNFa), interleukin 2 (IL-2) and interferon y (IFN'y) on mdrl gene expression at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level with monoclonal antibodies by immuno flow cytometry. P-glycoprotein function was examined after accumulation of the fluorescent drug, doxorubicin, by flow cytometry. Chemosensitivity to doxorubicin and vincristine was analysed using the XTT assay. All three cytokines were found to modulate the MDR characteristics on mdrl expression levels, P-glycoprotein function and measured chemosensitivity to MDRassociated anti-cancer drugs. This cytokine-induced reversal of MDR was strongly time dependent, with maximal effects after 48 and 72 h of cytokine treatment. If similar modulation of MDR phenotype can be obtained in in vivo models, it may be possible to verify the time course for modulation by cytokine treatment and to design appropriate clinical trials of this strategy for MDR reversal.
Successful chemotherapy of human cancers is often limited by resistance against structurally and functionally unrelated drugs (Germann et al., 1993; Roninson, 1991) . Multidrug resistance (MDR) represents a resistance mechanism with potential clinical relevance, frequently observed in tumours derived from tissues with excretory/secretory functions like colon, liver, kidney, etc. (Goldstein et al., 1989; Nooter and Herweijer, 1991) . The MDR phenotype is caused by overexpression of the mdrl gene encoding the P-glycoprotein, which is responsible for the energy-dependent extrusion of a variety of compounds, resulting in decreased concentrations of, e.g. chemotherapeutic drugs within the cells (Endicott and Ling, 1989; Valverde et al., 1992; Chin et al., 1993; Abraham et al., 1993; Roepe, 1995 (Lum et al., 1993; Raderer and Scheithauer, 1993) . Their effects on MDR reversal have been analysed by functional assays of P-glycoprotein, such as altered anticancer drug efflux and accumulation of fluorescent dyes, as well as through drug resistance assays. Although these compounds were examined in phase I/II trials showing activity in some cancers (Lum et al., 1993) , their clinical activity, as well as their mode of action for MDR reversal, remains controversial (Wadkins and Houghton, 1993; McLeod, 1994) .
Other strategies to overcome MDR include alteration of mdrl gene expression by antisense oligonucleotides, inhibition of P-glycoprotein function with antibodies, selection of cytotoxic drugs unaffected by P-glycoprotein, reduction of the availability of ATP, regional administration of modulators, or liposomal encapsulation of cytotoxic agents, as reviewed by Kellen (1993) . Most of these approaches are focused on modulation of P-glycoprotein function.
An alternative strategy for an efficient MDR reversal concerns the regulation of mdrl gene expression. Since it has been shown that tumour response rates may increase when treatment with conventional chemotherapeutic drugs is combined with cytokines (Wadler and Schwartz, 1990) , several cytokines were analysed for their capability to influence the MDR phenotype, and specifically, to modulate mdrl expression. So far, there are reports examining MDR modulation effects for TNF (Salmon et al., 1989; Kikuchi et al., 1992; Walther and Stein, 1994; Borsellino et al., 1994) , IFN a (Scala et al., 1991; Kikuchi et al., 1992; Kang and Perry, 1994; Fogler et al., 1995) , IFN y (Kikuchi et al., 1992; Walther and Stein, 1994) , IL-i a (Borsellino et al., 1994; Monti et al., 1994) , IL-2 (Walther and Stein, 1994) as well as for leukoregulin (Evans and Baker, 1992) , representing cytokines with different modes of action. Thus, it appears that cytokines are able to influence/overcome MDR phenotype and to enhance cytotoxicity of MDR-associated drugs to tumour cells. In most studies this has been shown by comparison of parental cells and resistant sublines. However, data obtained for cytokine-induced mdrl expression modulation on mRNA and/or protein level, have not been consistently described (Salmon et al., 1989; Scala et al., 1991; Evans and Baker, 1992; Walther and Stein, 1994; Kang and Perry, 1994) .
The present report provides a detailed investigation of the dependence on time and on cell line's MDR phenotype of cytokine-mediated effects on mdrl expression and chemosensitivity in cytokine-pretreated cells. The study presents new data, which may be important in planning improved combination therapy approaches for treatment of drugresistant tumours. The capability of the cytokines, TNFa, IL-2 and IFNy, to modulate/reverse the MDR phenotype was investigated. Our interest was focused on two human colon carcinoma cell lines, HCT15 and HCT116, which express different levels of mdrl mRNA/P-glycoprotein and, therefore, possess different P-glycoprotein-mediated MDR phenotypes. Cells of both lines were incubated with 100 U ml-' TNFa, IL-2 or IFNy for 2, 12, 24, 48 and 72 h respectively. Cytokine-induced effects were examined on the mdrl mRNA level by reverse transcription-polymerase chain reaction (RT-PCR), on the P-glycoprotein level with monoclonal antibodies by immuno flow cytometry, on the HCT1 16 (Brattain et al., 1981) , were selected from the 62 cell line panel of the National Cancer Institute, USA, which is extensively used for screening assays of new anti-cancer drugs. These cell lines are well characterised, including their properties of resistance phenotypes as well as their expression levels of resistance-associated genes like mdrl (Wu et al., 1992; Izquierdo et al., 1996) . Therefore, both cell lines possess the P-glycoprotein-mediated type of MDR intrinsically, with the higher MDR rank for HCT15 compared with HCT1 16.
Cells were grown in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS; Hy Clone, Logan, UT, USA) and 5 mM L-glutamine at 37°C and 5% carbon dioxide.
Cytokine treatment
To analyse the influence of cytokines on mdrl expression, 1 x 105 colon carcinoma cells were seeded into each well of 24-well dishes (Costar, Cambridge, MA, USA) and were cultured for 12 h in 1 ml medium. To test cytokine sensitivity in HCT1 5 and HCT1 16 cells, concentrations of 10 U ml -', 100 U ml-' and 1000 U ml-' of TNF, IL-2 and IFN 'y were tested for 2, 12, 24, 48 and 72 h. Both cell lines did not show antiproliferative or cytotoxic response to either cytokine at 10 or 100 U ml-'; however, 1000 U ml-' of TNF, IL-2 or IFN 7 caused significant growth-inhibitory effects, indicating that the latter concentrations could not be used for the study. Furthermore, since earlier experiments have shown that 100 U ml-' of TNF, IL-2 or IFN y are suitable for combination experiments with cytostatic drugs, cytokine concentrations of 100 U ml-' were applied for all experiments in this study. Cells were treated with the recombinant cytokines TNF, IL-2 and IFN'y (Promega, Madison, WI, USA) at 37'C. After 2, 12, 24, 48 and 72 h, cytokinecontaining medium was removed and cells were used either for RNA isolation, P-glycoprotein detection by MRK16 or C219 or doxorubicin accumulation experiments.
RNA isolation and RT-PCR After washing the cells with 1 ml ice-cold 0.9% sodium chloride solution, they were harvested by addition of 200 pl lithium chloride/urea (3 M lithium chloride, 6 M urea; Sigma, St Louis, MO, USA). Total RNA was prepared using the miniprep-RNA protocol . RT-PCR was performed with the Gene Amp RNA PCR kit (Perkin Elmer via Roche Molecular Systems Inc., Branchburg, NJ, USA). The RT reaction was performed using 1 pg of each miniprep-RNA with the random hexamer primers supplied with the kit. PCR was carried out using mdrl-specific primers (Noonan et al., 1990 ) producing a 167 bp product, or fl-actinspecific primers (Wu et al., 1992 ) producing a 316 bp product. Steps for RT were as follows: the RT reaction was run at 42°C for 15 min, followed by an RT-inactivating denaturation step at 95°C for 5 min and a cooling step at 5°C for 5 min. Amplification was performed initially at 95°C for 2 min, continued for 35 cycles of melting (950C for 1 min) Chemosensitivity assay Chemosensitivity of tumour cell lines was determined by using the XTT (2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide) cytotoxicity assay (Scudiero et al., 1988 (Figure 2) . Thus, the MRK16-detected P-glycoprotein expression in the more Figure 2 . In HCT15 cells (Figure 2a) Figure 3 , confirming the time dependence as well as the cell type specificity of the cytokine-modulated Pglycoprotein expression. In HCT15 cells (Figure 3a) (Figures 5 and 6) .
For all combinations of cytokines and drugs (TNF, IL-2 or IFNy plus doxorubicin, Figure 5 a-c and 6 a-c; TNF, IL-2 or IFNy plus vincristine, Figure 5 d-f and 6 d-f), cytotoxicity was enhanced by cytokine pretreatment. In general, increase in cytotoxicity was time dependent with a maximum enhancement after cytokine preincubations for 48 and 72 h. Although the cytokine-induced enhancement of cytotoxicities of the MDR-associated drugs, doxorubicin and vincristine, were seemingly independent from the cytokine used, the highest increase was achieved by TNF.
To evaluate the sensitising effects of cytokine pretreatments in the two tumour lines, the IC50 values for doxorubicin and vincristine were determined for untreated and cytokine-treated (pretreatment or simultaneous treatment) cells and their ratio was given as dose-modifying factors (DMFs) ( Table I) . Thus, after 48 and 72 h of cytokine pretreatment, significantly increased cytotoxicities were observed for all combinations analysed in both cell lines.
For example, in vincristine-treated HCT1 16 cells, DMFs of 17.3 (48 h) and 21.6 (72 h) were measured for TNF pretreatment (P< 0.00009). In highly resistant vincristinetreated HCT15 cells, DMFs of 5.3 (48 h) and 9.0 (72 h) were determined (P < 0.0002). In contrast to pretreated cells, simultaneous incubation of cytokine and anti-cancer drug did not result in a significant increase of cytotoxicity, either for doxorubicin or for vincristine.
Discussion
Colorectal cancer is one of the leading causes of cancer morbidity and mortality in the world (Goldstein et al., 1989) . Although there has been extensive research on a variety of chemotherapeutic treatment regimens, a decisive success in increasing survival time of patients with colorectal cancer has yet to be achieved. Since overexpression of mdrl gene in normal human colorectal tissue, as well as in human colorectal cancer, has been described frequently (Mizoguchi et al., 1990; Park et al., 1990; Lai et al., 1991) , this intrinsic or acquired resistance against MDR-associated drugs, like doxorubicin, vincristine or actinomycin D, might be a reason for the failure of chemotherapeutic treatments with these drugs. Thus, colon cancer may be an area in which MDR reversal strategies may have benefit. The sensitisation of this tumour type to drugs, which are originally not in favour for the treatment of colon cancer, might have a therapeutic impact and could broaden the spectrum of drugs for chemotherapy of this cancer.
In the present report, the capability of cytokines to modulate MDR has been investigated in the highly drugresistant HCT15 human colon carcinoma cell line and the HCT116 cell line, which manifests a lesser degree of multidrug resistance. In this study, cytokine effects as an approach for reversal of MDR were analysed on the mdrl mRNA level by RT-PCR, as well as on the P-glycoprotein level by using the monoclonal antibodies MRK16 and C219 and immuno flow cytometry. Cytokine-modulated P-glycoprotein function was examined by accumulation assays with the fluorescent MDR-associated drug, doxorubicin. Cytokineinfluenced MDR phenotypes of both cell lines were determined by XTT chemosensitivity assays with doxorubicin and vincristine. The following results were achieved: (1) cytokines were able to decrease mdrl expression on the mRNA as well as on the P-glycoprotein level; (2) these effects were reflected in P-glycoprotein function; (3) cytokines augment the cytotoxicity of the MDR-associated drugs, doxorubicin and vincristine; (4) cytokines act in a timedependent manner with maximum down-regulation in mdrl mRNA and P-glycoprotein levels after 48 h treatment; and finally, (5) cytokines modulate mdrl expression, P-glycoprotein function as well as drug sensitivity. These results confirm and extend our earlier data describing cytokine-mediated alteration of mdrl expression . In this study, we give evidence of dependence on time and on the cell line's MDR phenotype of these cytokine activities. It is further shown that cytokines are able to enhance cytotoxicities of MDR-associated drugs, expressed by reduced IC50 for doxorubicin and vincristine. The cytokine-mediated sensitisation of human tumour cells was manifested as a reversal of the MDR phenotypes of both cell lines. Cytokine treatment caused a decrease of mdrl expression, as well as the increase of doxorubicin accumulation and resultant cytotoxicity. Although our data suggest that cytokine treatment sensitises cell lines to cheniotherapeutic drugs through a P-glycoproteinmediated mechanism, because there is no strict correlation between relative MDR ranking and relative P-glycoprotein in colon carcinoma cell lines (Izquierdo et al., 1996) , we cannot rule out the possibility that cytokines are also working in these cell lines through one or more non-P-glycoprotein-mediated mechanisms.
Some studies have described effects of externally added cytokines on MDR phenotypes, but only a few of them analysed the cytokine-induced modulation of mdrl gene expression on both the mRNA and P-glycoprotein level (Salmon et al., 1989; Scala et al., 1991; Evans and Baker, 1992; Walther and Stein, 1994; Kang and Perry, 1994) . There were no alterations found for mdrl expression on mRNA levels in human drug-sensitive and -resistant leukaemia and myeloma cell lines 24 h after cytokine treatment (Salmon et al., 1989) . This represents exactly the same incubation time in which we are also unable to detect significant changes in HCT15 and HCT116 cells. Studies investigating the effects caused by IFNa include one report which described increased mdrl expression on RNA and protein level within treatment intervals of up to 24 h in the Chinese hamster ovary cell line Chr C5 (Kang and Perry, 1994) , and one report showing unchanged P-glycoprotein expression in LoVo colon carcinoma cells (Scala et al., 1991) . For a panel of 21 known or newly discovered cytokines, including TNF, IL-2, IFNo and IFNy, unaffected P-glycoprotein levels were observed with cytokine treatments of 2 h, except for the cytokine, leukoregulin, which caused decreased mdrl expression (Evans and Baker, 1992) . Elevated accumulation of fluorescent P-glycoprotein substrates, like rhodamine 123 or doxorubicin, after cytokine treatment have been reported for the cytokines TNF, IFNa, IL-la and leukoregulin (Scala et al., 1991; Evans and Baker, 1992; Valenti et al., 1993; Borsellino et al., 1994) , reflecting a sensitisation of the MDR phenotype in these cells. Interestingly, in contrast to the contradictory results described for cytokine effects on mdrl expression, investigations are in rather good agreement concerning cytokine-induced P-glycoprotein function. The greatest agreement concerning cytokine-altered MDR phenotypes was reported for TNF, IFNa, IFNy, IL-2 and IL-la and leukoregulin, based on chemosensitivity experiments with Vincristine (ng ml-1 ) Vincristine (ng ml-1) Vincristine (ng ml-1 ) the MDR-associated cytotoxic drugs like doxorubicin, vincristine or actinomycin D (Scala et al., 1991; Evans and Baker, 1992; Kikuchi et al., 1992; Monti et al., 1993; Valenti et al., 1993; Walther and Stein, 1994; Borsellino et al., 1994; Kamikaseda et al., 1994) . Moreover, MDR reversal results have been described for combination of cytokines (e.g. IFNa) with agents that inhibit P-glycoprotein function, like monoclonal antibodies, such as MRK16 (Fogler et al., 1995) , as well as for a combination with verapamil (Kang and Perry, 1994) . Interestingly, chemosensitivity assays have shown that cytokines of different origins and modes of action cause the same effect: they are capable of MDR reversal. In this-study we describe the modulatory effects on mdrl expression and function as well as on cytotoxicities of MDR-related drugs caused by TNF, IL-2, and IFNy. The finding that these cytokines exert the same effect could be explained by the wellaccepted fact that cytokines act with redundancy and pleiotropy in very different cell types (for review see Kroemer et al., 1993) . Another possible mechanism of action of these three cytokines could be the induction of expression of at least one major active cytokine which, in turn, may be responsible for the modulation of mdrl expression. This hypothesis is supported by the findings of cytokine cascades (Kroemer et al., 1993) . It is well known that, e.g. TNF expression is inducible by IL-2 or IFNy (Sidhu and Bollon, 1993) , and it will be of great interest to determine whether such a mechanism of cytokine induction takes place in treated tumour cells.
The potential of cytokines for MDR reversal, especially in highly resistant tumour cells, makes cytokine pretreatment an attractive approach for improved chemotherapy of these tumours. The present results suggest additional possibilities for more sophisticated combination therapies involving cytokines and MDR-related drugs.
